Theratechnologies Inc. Income Statement

Ask AI

Financial Statements

In millions of USD, except per-share amounts

	FY2024 12 months to Nov 30, 2024	FY2023 12 months to Nov 30, 2023	FY2022 12 months to Nov 30, 2022	FY2021 12 months to Nov 30, 2021	FY2020 12 months to Nov 30, 2020
Revenue
Operating expenses
Cost of goods sold
Other production-related costs
Amortization of other asset
Research and development expenses net of tax credits of $296 (2019 – nil)
Research and development expenses, net of tax credits of $ 1,666 (2023 - $ 539; 2022 – $ 316)
Selling expenses
General and administrative expenses
Total operating expenses
Profit (loss) from operating activities
Finance income
Finance costs
Finance income cost
Loss before income taxes
Income tax expense
Net loss

Other comprehensive income (loss), net of tax
Items that may be reclassified to net profit (loss) in the future
Net change in fair value of financial assets at fair value through other comprehensive income ("FVOCI")
Exchange differences on translation of foreign operations
Other comprehensive income that will be reclassified to profit or loss, net of tax
Total comprehensive loss
Loss per share
Basic and diluted
Basic earnings (loss) per share
Diluted earnings (loss) per share

Comments